Adeka (4401) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
27 Apr, 2026Executive summary
Net sales for the nine months ended December 31, 2025, were ¥296.7 billion, up 0.1% year-over-year, with operating profit at ¥29.3 billion, down 2.6%, and profit attributable to owners at ¥19.8 billion, up 3.4%.
Ordinary profit increased by ¥0.7 billion year-over-year to ¥30.3 billion.
Earnings per share rose to ¥196.9, an increase of ¥8.4 per share year-over-year.
Comprehensive income surged 51.8% year-over-year to ¥36,307 million.
Financial highlights
Gross profit for the period was ¥84,752 million, up from ¥84,034 million year-over-year.
Operating margin for the nine months was approximately 9.9%.
Net margin attributable to owners of parent was about 6.7%.
Overseas sales ratio stands at approximately 54%.
Annual dividend forecast maintained at ¥104 per share, with a payout ratio target of 40% or more.
Outlook and guidance
Full-year net sales forecast revised to ¥415 billion, up 1.9% year-over-year; operating and ordinary profit each forecast at ¥41.5 billion.
Profit attributable to owners of parent projected at ¥25.5 billion, up 1.9% year-over-year.
Earnings per share forecast at ¥257.7.
Recovery in polymer additives and semiconductor materials expected in Q4, with new product launches and market recovery anticipated.
Food products and life science segment outlooks remain unchanged; life science expects steady demand but higher fixed costs.
Latest events from Adeka
- Q1 earnings fell on volume weakness; FY profit targets stayed intact.document-source184401
Q1 2024 - Record FY2023 profits set the stage for ADX 2026 growth and JPY 75 billion in CapEx.4401
Q4 2024 - Pricing and FX cushioned volume-led pressure as FY2023 guidance remained unchanged.4401
Q3 2024 - Strong sales and profit growth led by chemicals and semiconductors; outlook and dividends raised.4401
Q1 2027 - Record FY2025 results; FY2026 forecasts further growth but exclude Middle East impacts.4401
Q4 2026 - H1 growth lifted FY2024 guidance and dividends, led by Chemicals.4401
Q2 2025 - Nine-month profit rose 25.1%, led by Chemicals, as semiconductor investment advanced.4401
Q3 2025 - Record FY2024 results, with FY2025 growth forecast amid tariff and cost risks.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026